TWI475984B - Method for making an infill structure - Google Patents
Method for making an infill structure Download PDFInfo
- Publication number
- TWI475984B TWI475984B TW099111336A TW99111336A TWI475984B TW I475984 B TWI475984 B TW I475984B TW 099111336 A TW099111336 A TW 099111336A TW 99111336 A TW99111336 A TW 99111336A TW I475984 B TWI475984 B TW I475984B
- Authority
- TW
- Taiwan
- Prior art keywords
- biomedical material
- mold
- manufacturing
- master mold
- biomedical
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 17
- 239000003519 biomedical and dental material Substances 0.000 claims description 83
- 238000004519 manufacturing process Methods 0.000 claims description 33
- 238000011049 filling Methods 0.000 claims description 26
- 238000001035 drying Methods 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 16
- 239000004971 Cross linker Substances 0.000 claims description 15
- 238000003825 pressing Methods 0.000 claims description 10
- 239000012567 medical material Substances 0.000 claims description 5
- 239000011800 void material Substances 0.000 claims description 5
- 238000004132 cross linking Methods 0.000 claims description 4
- 230000035484 reaction time Effects 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 description 13
- 239000000463 material Substances 0.000 description 11
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 239000001506 calcium phosphate Substances 0.000 description 6
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 6
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 6
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 6
- 229940078499 tricalcium phosphate Drugs 0.000 description 6
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 6
- 235000019731 tricalcium phosphate Nutrition 0.000 description 6
- 230000000399 orthopedic effect Effects 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 4
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 4
- 238000001125 extrusion Methods 0.000 description 4
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- AZKVWQKMDGGDSV-BCMRRPTOSA-N Genipin Chemical compound COC(=O)C1=CO[C@@H](O)[C@@H]2C(CO)=CC[C@H]12 AZKVWQKMDGGDSV-BCMRRPTOSA-N 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 239000005312 bioglass Substances 0.000 description 3
- 150000001718 carbodiimides Chemical class 0.000 description 3
- 238000010382 chemical cross-linking Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- AZKVWQKMDGGDSV-UHFFFAOYSA-N genipin Natural products COC(=O)C1=COC(O)C2C(CO)=CCC12 AZKVWQKMDGGDSV-UHFFFAOYSA-N 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 230000003239 periodontal effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 210000005189 upper gingiva Anatomy 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010020346 Polyglutamic Acid Proteins 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229920002643 polyglutamic acid Polymers 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- FZHAPNGMFPVSLP-UHFFFAOYSA-N silanamine Chemical compound [SiH3]N FZHAPNGMFPVSLP-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- -1 acyl azide Chemical class 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000515 collagen sponge Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Landscapes
- Prostheses (AREA)
Description
本發明是關於填充結構的製造方法,特別是具有不同的緻密度的填充結構製造方法。The present invention relates to a method of making a filled structure, and more particularly to a method of making a filled structure having different densities.
一般而言,在完成拔牙手術後的治療過程中,以牙根周圍組織的修復與再生特別重要,因為如果沒有妥善的進行修復處理,而在手術拔牙後放任傷口自然癒合,則一年內缺牙的齒槽骨高度與寬度可能會萎縮達40%-60%。造成萎縮的原因,主要是因為位於下方的齒槽骨的再生修復速度,較位於上方牙齦的再生修復速度來的緩慢,造成上方的牙齦除了橫向生長外,並會沿著缺牙的齒槽向下擴張,進而造成齒槽骨高度與寬度的萎縮。In general, it is particularly important to repair and regenerate the tissue surrounding the root during the treatment after the tooth extraction operation, because if the repair is not properly performed, and the wound is naturally healed after the surgical extraction, the tooth is missing within one year. The height and width of the alveolar bone may shrink by 40%-60%. The reason for the atrophy is mainly because the regenerative repair speed of the alveolar bone located below is slower than that of the upper gingiva, which causes the upper gingiva to move along the sulcus of the missing tooth in addition to the lateral growth. Lower expansion, which in turn causes atrophy of the height and width of the alveolar bone.
此外,因為原來牙齒列排列的很緊密,所以缺牙的齒槽往往會受到側向擠壓的力量,而改變原來牙齒排列的平衡。比如缺牙齒的下頷,使後側鄰牙向前傾倒,造成日後裝設假牙或進行人工植牙的困難。更者,由於缺牙的齒槽骨高度與寬度已大幅萎縮,在植牙前可能還需要先進行手術,切除多餘的牙齦,以提供植牙所需的高度與寬度。In addition, because the original tooth rows are arranged very tightly, the missing tooth grooves tend to be subjected to lateral compression forces, which change the balance of the original tooth arrangement. For example, the lack of teeth in the lower jaw, so that the back side of the adjacent teeth dumped forward, resulting in the difficulty of installing dentures or artificial implants in the future. Moreover, because the height and width of the alveolar bone of the missing tooth has shrunk significantly, it may be necessary to perform surgery to remove excess gingiva before implanting to provide the height and width required for implanting.
目前針對拔牙後所進行的修補,是使用人造物填入缺牙的齒槽中。比如使用骨質增生膠原蛋白(collagen sponge)做為人造填充物,並搭配手術填入缺牙的齒槽中,以減少齒槽骨高度與寬度的萎縮。不過此法的缺點是齒槽骨高度與寬度仍會有些許萎縮,其原因在於人造物並無阻隔的作用,仍舊無法隔絕位於上方的牙齦向下生長,而在維持一個提供細胞生長的空間,因此齒槽骨高度與寬度仍有可能萎縮。The current repair for tooth extraction is to use artificial objects to fill the missing teeth. For example, collagen sponge is used as an artificial filler and surgically filled into the gullet of the missing tooth to reduce the atrophy of the height and width of the alveolar bone. However, the disadvantage of this method is that the height and width of the alveolar bone are still slightly shrunk. The reason is that the artificial object has no blocking effect, and it is still impossible to isolate the upper gingiva from growing downward, while maintaining a space for providing cell growth. Therefore, the height and width of the alveolar bone may still shrink.
習知技術中的另一種方式,是在牙齦以及齒槽骨的交界處放置一牙周再生膜,以便在齒槽中隔絕出一空間,提供牙周組織再生。不過此種方式由於是完全依靠齒槽骨的自我修復與再生,並無借助其他的藥物治療,因此其修復所需要的時間較長。另外,習知之另一種人造物1為包含以膠質海綿體10所構成的生醫材料。請參照圖1,為一習知的人造物示意圖,人造物1為由一個膠質海綿體10和一薄膜11組成,其中薄膜11是用化學交聯劑(chemical cross-linker)黏接於膠質海綿體10的一端。Another way in the prior art is to place a periodontal regeneration membrane at the junction of the gums and the alveolar bone to isolate a space in the alveolar to provide periodontal tissue regeneration. However, this method takes a long time to repair because it relies entirely on the self-repair and regeneration of the alveolar bone without any other medical treatment. In addition, another artificial object 1 of the prior art is a biomedical material comprising a colloidal sponge 10. Please refer to FIG. 1 , which is a schematic diagram of a conventional artificial object. The artificial object 1 is composed of a colloidal sponge 10 and a film 11 , wherein the film 11 is bonded to the colloidal sponge by a chemical cross-linker. One end of the body 10.
不過此種方式的缺點在於,由於膠質海綿體10和薄膜11、黏著劑其材料性質不同;膠質海綿體10和薄膜11兩者的接觸面積以及其表面的平坦度...等差異,因此介面的黏接會產生許多問題,比如黏接不易,以至於在黏著的介面處發生鬆脫的問題;所施加的化學交聯劑(chemical cross-linker)可能會太多或太少,不易掌控,造成化學交聯劑(chemical cross-linker)浪費或是有黏接不牢的問題。However, the disadvantage of this method is that the material properties of the colloidal sponge 10 and the film 11 and the adhesive are different; the contact area of the colloidal sponge 10 and the film 11 and the flatness of the surface thereof are different, and thus the interface The bonding can cause many problems, such as the difficulty of bonding, so that the problem of loosening occurs at the adhesive interface; the chemical cross-linker applied may be too much or too little to be controlled. Causes a chemical cross-linker to be wasted or has a problem of poor adhesion.
爰此,如何能夠改善目前人造物的製造問題,是相關業者致力解決的目標。Therefore, how to improve the current manufacturing problems of man-made objects is the goal that the relevant industry is committed to.
本發明的目的是提供填充結構的製造方法,特別是具有不同之緻密度的填充結構製造方法。It is an object of the present invention to provide a method of making a filled structure, particularly a method of making a filled structure having a different density.
本發明的另一個目的是提供可取代現有用於組織修復的填充結構製造方法。Another object of the present invention is to provide a method of manufacturing a filling structure that can replace existing tissue repairs.
本發明的另一個目的是提供解決缺牙後牙周組織缺損問題的填充結構製造方法。Another object of the present invention is to provide a method of manufacturing a filling structure that solves the problem of periodontal tissue defects after occlusion.
本發明的另一個目的是提供應用於骨科的填充結構製造方法。Another object of the present invention is to provide a method of manufacturing a filling structure for use in orthopedics.
本發明的另一個目的是提供較快速且較方便的填充結構製造方法。Another object of the present invention is to provide a faster and more convenient method of manufacturing a filled structure.
本發明提供的填充結構製造方法,包含提供一模具,模具包含一母模與一公模;注入一生醫材料於母模中,使生醫材料上表面高於母模的上表面;壓合母模與公模,藉此對生醫材料的上表面進行擠壓,使生醫材料上側部份的密度大於下側部份的密度;乾燥生醫材料;且由母模中取出生醫材料。The method for manufacturing a filling structure provided by the present invention comprises providing a mold comprising a mother mold and a male mold; injecting a raw medical material into the female mold, so that the upper surface of the biomedical material is higher than the upper surface of the female mold; The mold and the male mold are used to squeeze the upper surface of the biomedical material so that the density of the upper part of the biomedical material is greater than the density of the lower part; the biomedical material is dried; and the biomedical material is taken out from the female mold.
由於本發明提供的填充結構製造方法,本發明的一項優點為可提供具有不同之緻密度的填充結構,可解決不同性質材料介面黏接的問題、解決使用化學交聯劑(chemical cross-linker)而衍生的各種問題,並且可以用較方便的方式製造。Because of the filling structure manufacturing method provided by the present invention, an advantage of the present invention is that it can provide filling structures with different densities, can solve the problem of interface bonding of materials of different properties, and solve the problem of using chemical cross-linker (chemical cross-linker). And various problems derived from it, and can be manufactured in a more convenient manner.
關於本發明所述的填充結構製造方法,可以藉由以下發明詳述及所附圖示,得到進一步的瞭解。Further, the method for producing a filling structure according to the present invention can be further understood from the following detailed description of the invention and the accompanying drawings.
請參照圖2,此圖顯示本發明第一實施例中,填充結構2的製作方法。其製作方法包含步驟(S1)提供一模具20,其中模具20包含一母模201與一公模202。接著,進行步驟(S2),注入一生醫材料21於母模201中。再進行步驟(S3),壓合母模201與公模202,藉此對生醫材料21的上表面進行擠壓,使生醫材料21上側部份的密度大於下側部份的密度。之後進行步驟(S4),乾燥生醫材料21。最後進行步驟(S5),由母模201中取出生醫材料21。Referring to FIG. 2, there is shown a method of fabricating the filling structure 2 in the first embodiment of the present invention. The manufacturing method comprises the step (S1) of providing a mold 20, wherein the mold 20 comprises a female mold 201 and a male mold 202. Next, the step (S2) is performed to inject a biomedical material 21 into the master mold 201. Further, the step (S3) is performed to press the master 201 and the male mold 202, whereby the upper surface of the biomedical material 21 is pressed so that the density of the upper portion of the biomedical material 21 is greater than the density of the lower portion. Thereafter, the step (S4) is carried out to dry the biomedical material 21. Finally, the step (S5) is carried out, and the biomedical material 21 is taken out from the master 201.
請參閱圖2a與圖2b,其顯示了本發明步驟(S1)至(S2)的過程。首先提供模具20,然後圖2b顯示注入生醫材料21於母模201中之步驟(S2),其中生醫材料21上表面高於母模201的上表面,也就是說所加入的生醫材料21是比原先所製造成之成品更多一點之多孔性生醫材料21。並且,在一實施例中,會先略微乾燥母模201內之生醫材料21,使母模201內之生醫材料21具有海綿狀之雛形,再進行步驟(S3)。Referring to Figures 2a and 2b, the process of steps (S1) through (S2) of the present invention is shown. First, a mold 20 is provided, and then FIG. 2b shows a step (S2) of injecting the biomedical material 21 into the master mold 201, wherein the upper surface of the biomedical material 21 is higher than the upper surface of the mother mold 201, that is, the biomedical material to be added. 21 is a porous biomedical material 21 that is a little more than the original manufactured product. Further, in an embodiment, the biomedical material 21 in the female mold 201 is slightly dried first, so that the biomedical material 21 in the female mold 201 has a spongy shape, and the step (S3) is performed.
其中,生醫材料21的材料為具有多孔性的生醫材料,來源包括膠原蛋白(collagen)、明膠(gelatin)、玻尿酸(hyaluronic acid)、幾丁聚醣(chitosan)、幾丁質(chitin)、聚麩酸(poly glutamic acid,PGA)、氫氧基磷灰石(hydroxyapatite,HAP)、磷酸三鈣(tricalcium phosphate,TCP)、生醫玻璃(bioglass)。其中,當使用於齒槽骨填充結構製備時,生醫材料21其較佳實施例為選用膠原蛋白(collagen)、明膠(gelatin)...等。另外,當使用於骨科材料製備時,生醫材料21較佳實施例為選用氫氧基磷灰石(hydroxyapatite,HAP)、磷酸三鈣(tricalcium phosphate,TCP)、生醫玻璃(bioglass)、玻尿酸(hyaluronic acid,HA)...等。Among them, the material of the biomedical material 21 is a porous biomedical material, and the sources include collagen, gelatin, hyaluronic acid, chitosan, chitin. Polyglutamic acid (PGA), hydroxyapatite (HAP), tricalcium phosphate (TCP), bioglass. Among them, when used in the preparation of the alveolar bone filling structure, the preferred embodiment of the biomedical material 21 is collagen, gelatin, and the like. In addition, when used in the preparation of orthopedic materials, the preferred embodiment of the biomedical material 21 is hydroxyapatite (HAP), tricalcium phosphate (TCP), bioglass, hyaluronic acid. (hyaluronic acid, HA)...etc.
在步驟(S2)之後,且進行步驟(S3)之前,還可包括添加一化學性交聯劑(chemical cross-linker)於生醫材料21上表面的步驟(S21),如圖2b所示。其中,化學性交聯劑(chemical cross-linker)可選自戊二醛(glutaraldehyde)、碳二亞胺(carbodiimide)、胺基矽烷(aminosilane)、綠梔子素(genipin)、六甲烯基二異氰酸鹽(hexamethylene diisocyanate,HMDI)、甲醛(formaldehyde)、醯疊氮(acyl azide)。當然,其亦可使用其他等效之化學性交聯劑(chemical cross-linker),來達到化學交聯之目的。在一較佳實施例中,使用的化學性交聯劑(chemical cross-linker)可選擇戊二醛,並且,戊二醛的最佳使用濃度約為0.001%~3.000%。而在另一較佳實施例中,使用的化學性交聯劑(chemical cross-linker)可選擇1-(3-二甲氨基丙基)-3-乙基碳二亞胺鹽酸鹽(1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride,EDC)(碳二亞胺的一種化合物),並且EDC的最佳使用濃度約為1~300mM。After the step (S2), and before the step (S3), a step of adding a chemical cross-linker to the upper surface of the biomedical material 21 (S21) may be further included, as shown in FIG. 2b. Wherein, the chemical cross-linker may be selected from the group consisting of glutaraldehyde, carbodiimide, aminosilane, genipin, hexamethylenyl diiso. Cyanate (hexamethylene diisocyanate, HMDI), formaldehyde (formaldehyde), acyl azide. Of course, it can also use other equivalent chemical cross-linkers to achieve chemical cross-linking. In a preferred embodiment, the chemical cross-linker used may be selected from glutaraldehyde, and the optimum use concentration of glutaraldehyde is from about 0.001% to 3.000%. In another preferred embodiment, the chemical cross-linker used may be selected from 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1- Ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC), a compound of carbodiimide, and an optimum concentration of EDC of about 1 to 300 mM.
舉例來說,當化學性交聯劑(chemical cross-linker)使用於交聯膠原蛋白或其他之生物分子時,較佳實施例依其應用範圍之機械強度的不同而可選用戊二醛(glutaraldehyde)、碳二亞胺(carbodiimide)、綠梔子素(genipin)...等。倘若欲交聯之生醫材料為氫氧基磷灰石(hydroxyapatite,HAP)、磷酸三鈣(tricalcium phosphate,TCP)、生醫玻璃(bioglass)...或其他生醫材料時,其化學交聯劑(chemical cross-linker)之較佳實施例為胺基矽烷(aminosilane)、六甲烯基二異氰酸鹽(hexamethylene diisocyanate,HMDI)、綠梔子素(genipin)...等。For example, when a chemical cross-linker is used to crosslink collagen or other biomolecules, the preferred embodiment may use glutaraldehyde depending on the mechanical strength of the application range. , carbodiimide, genipin, etc. If the biomedical material to be cross-linked is hydroxyapatite (HAP), tricalcium phosphate (TCP), bioglass, or other biomedical materials, its chemical interaction Preferred examples of the chemical cross-linker are aminosilane, hexamethylene diisocyanate (HMDI), genipin, and the like.
其中,在進行步驟(S21)之後,且進行步驟(S3)之前,還包括靜置生醫材料21(S22)的步驟,藉此使生醫材料21產生化學性交聯,其中反應的時間為30分鐘~24小時;並且,較佳實施反應時間為30分鐘~6小時。Wherein, after the step (S21) is performed, and before the step (S3) is performed, the step of resting the biomedical material 21 (S22) is further included, thereby causing the biomedical material 21 to be chemically cross-linked, wherein the reaction time is 30. Minutes to 24 hours; and, preferably, the reaction time is from 30 minutes to 6 hours.
請參照圖2b與圖2c,其顯示了本發明步驟(S2)至(S3)的過程。在本發明一實施例中,當壓合母模201與公模202,藉此對生醫材料21的上表面進行擠壓的步驟(S3)時,會持續擠壓至生醫材料上側部份211之孔隙度介於0.1%~30%,而生醫材料下側部份212之孔隙度介於50%~99%。Referring to Figures 2b and 2c, the process of steps (S2) through (S3) of the present invention is shown. In an embodiment of the present invention, when the master mold 201 and the male mold 202 are pressed, thereby pressing the upper surface of the biomedical material 21 (S3), the upper portion of the biomedical material is continuously extruded. The porosity of 211 is between 0.1% and 30%, and the porosity of the lower portion 212 of the biomedical material is between 50% and 99%.
當然,壓合母模201與公模202,藉此對生醫材料21的上表面進行擠壓的步驟(S3),公模202可以選擇為一板塊,而母模201此時為一凹槽,壓合母模201與公模202來對生醫材料21的上表面進行擠壓,如圖2c所示。當然,母模201與公模202可根據填充結構形狀而有其他的設計,並不以上述所提到的實施例為限。Of course, the step of pressing the master 201 and the male mold 202, thereby pressing the upper surface of the biomedical material 21 (S3), the male mold 202 can be selected as a plate, and the female mold 201 is a groove at this time. The male mold 201 and the male mold 202 are pressed to press the upper surface of the biomedical material 21 as shown in Fig. 2c. Of course, the female mold 201 and the male mold 202 may have other designs depending on the shape of the filling structure, and are not limited to the above-mentioned embodiments.
其中,公模202的溫度可控制在70℃~150℃,藉此可使受到擠壓的生醫材料21上表面產生熱交聯。當公模202的溫度範圍70℃~150℃時,所需加熱時間約為30分鐘~24小時;其中,較佳實施反應時間為30分鐘~6小時。Wherein, the temperature of the male mold 202 can be controlled at 70 ° C to 150 ° C, whereby the upper surface of the extruded biomedical material 21 can be thermally crosslinked. When the temperature of the male mold 202 ranges from 70 ° C to 150 ° C, the heating time is about 30 minutes to 24 hours; wherein the preferred reaction time is 30 minutes to 6 hours.
公模202除了可以選擇為一板塊外,其板塊上還可具有複數個細微的空隙孔洞,每一孔洞為大小約為100μm~2mm,以使公模202、母模201在壓合後,生醫材料21能快速乾燥。The male mold 202 can be selected as a plate, and the plate can also have a plurality of fine void holes, each of which has a size of about 100 μm to 2 mm, so that the male mold 202 and the female mold 201 are pressed together. Medical material 21 can be dried quickly.
另外,請參照圖3,顯示了本案另一實施例,此實施例是為了加速公模202、母模30壓合完畢之後,生醫材料21能較快速乾燥,針對母模30所做的特殊設計。其中,母模30以雙層結構方式所構成,意即母模30由一母模內層301與一母模外層302所構成,且母模內層301置於母模外層302中,也就是說母模外層302尺寸略大於母模內層301,母模內層301與母模外層302可套合為一,所構成的母模30為圓筒狀。其中母模內層301具有複數個空隙孔洞,母模外層302無孔洞。母模內層301上的每一孔洞為大小約為100μm~2mm。在本實施例中,母模內層301表面具有複數個孔洞,目的在希望減少生醫材料乾燥所需時間;母模外層302則為防止注入母模30之生醫材料溶液在未形成海綿狀體前經由母模內層301流失掉。In addition, referring to FIG. 3, another embodiment of the present invention is shown. This embodiment is to accelerate the drying of the male mold 202 and the female mold 30 after the male mold 202 is pressed, and the special medical material 21 can be dried relatively quickly. design. Wherein, the master mold 30 is constructed in a two-layer structure, that is, the master mold 30 is composed of a mother mold inner layer 301 and a mother mold outer layer 302, and the mother mold inner layer 301 is placed in the mother mold outer layer 302, that is, It is said that the outer layer 302 of the mother mold is slightly larger in size than the inner layer 301 of the mother mold, and the inner layer 301 of the mother mold and the outer layer 302 of the mother mold can be sleeved into one, and the mother mold 30 is formed into a cylindrical shape. The inner mold layer 301 has a plurality of void holes, and the outer mold layer 302 has no holes. Each hole in the inner layer 301 of the mother mold has a size of about 100 μm to 2 mm. In this embodiment, the inner surface of the inner mold layer 301 has a plurality of holes for the purpose of reducing the time required for the drying of the biomedical material; the outer layer 302 of the mother mold is for preventing the injection of the biomedical material solution into the female mold 30 without forming a sponge. The body is lost through the inner mold layer 301.
經過(S3)步驟擠壓後的生醫材料21,其上側部份211的密度會大於下側部份212的密度,從而得到不同緻密度的生醫材料21,此時生醫材料21為多孔性生醫材料21,如圖2c所示。在一實施例中,生醫材料21為多孔性材料,其上側部份211為緻密層,其中每一孔洞直徑小於30μm,孔隙度介於0.1%~30%;生醫材料21下側部份212具有複數個孔洞,每一孔洞直徑大於50μm,較佳實施例為介於50~300μm,孔隙度介於50%~99%。在一實施例中,壓合母模201與公模202,藉此對生醫材料21的上表面進行擠壓的步驟(S3)中,是擠壓生醫材料21至生醫材料21的下側部份的孔隙度介於50%~99%,而生醫材料21上側部份的孔隙度介於0.1%~30%,才完成步驟(S3)。After the biomedical material 21 extruded in the (S3) step, the density of the upper portion 211 is greater than the density of the lower portion 212, thereby obtaining biomedical materials 21 of different densities, and the biomedical material 21 is porous. Sexual biomedical material 21, as shown in Figure 2c. In one embodiment, the biomedical material 21 is a porous material, and the upper portion 211 is a dense layer, wherein each hole has a diameter of less than 30 μm, a porosity of 0.1% to 30%, and a lower portion of the biomedical material 21 212 has a plurality of holes each having a diameter greater than 50 μm, preferably between 50 and 300 μm and a porosity between 50% and 99%. In one embodiment, the step of pressing the master mold 201 and the male mold 202, thereby pressing the upper surface of the biomedical material 21 (S3), is to squeeze the biomedical material 21 to the biomedical material 21 The porosity of the side portion is between 50% and 99%, and the porosity of the upper portion of the biomedical material 21 is between 0.1% and 30%, and the step (S3) is completed.
之後,在步驟(S4)乾燥生醫材料21中,是以冷凍乾燥、真空乾燥以及熱風乾燥的方式乾燥生醫材料21。而在一較佳實施例中,使用的乾燥方式為使用冷凍乾燥。其中,在一實施例中,在步驟(S4)乾燥生醫材料21中,是乾燥生醫材料21至生醫材料21下側部份之孔隙度介於50%~99%,而生醫材料21上側部份之孔隙度介於0.1%~30%,才完成步驟(S4)。Thereafter, in the step (S4) of drying the biomedical material 21, the biomedical material 21 is dried by freeze drying, vacuum drying, and hot air drying. In a preferred embodiment, the drying method used is the use of freeze drying. Wherein, in an embodiment, in the step (S4) drying the biomedical material 21, the porosity of the dry biomedical material 21 to the lower part of the biomedical material 21 is between 50% and 99%, and the biomedical material The porosity of the upper portion of 21 is between 0.1% and 30%, and the step (S4) is completed.
隨後,在步驟(S5)由母模201取出生醫材料21的步驟,是直到生醫材料21下側部份具有複數個孔洞,每一孔洞直徑介於50~300μm,而生醫材料21上側部份具有複數個孔洞,每一孔洞直徑小於30μm,才從201母模取出生醫材料21。如圖2d所示,其顯示了最後取出來的填充結構2具有不同的緻密度,其中上側部份211的密度會大於下側部份212的密度。Subsequently, the step of taking the biomedical material 21 from the master mold 201 in the step (S5) is until the lower portion of the biomedical material 21 has a plurality of holes each having a diameter of 50 to 300 μm, and the upper side of the biomedical material 21 The portion has a plurality of holes, each having a diameter of less than 30 μm, and the biomedical material 21 is taken out from the 201 female mold. As shown in Fig. 2d, it is shown that the finally removed filling structure 2 has a different density, wherein the density of the upper portion 211 is greater than the density of the lower portion 212.
另外,針對本案母模30以雙層結構方式所構成,填充結構2較詳細的製造方法,包括先將生醫材料21溶液注入母模30中,並將其乾燥數小時至數天,使生醫材料21之海綿狀結構已有雛形。接著,利用先前所提之公模202、母模30壓合來於生醫材料之上表面製造一緻密層。壓合完畢之後,於進行生醫材料乾燥之步驟之前,將公模202、母模30倒立放置,並將母模外層302取出,保留母模內層301,藉由母模內層301之複數個孔洞來加速材料乾燥過程;其中將公模202、母模30倒立放置之步驟並非必要,也就是說公模202、母模30並非一定需要倒立放置。此實施例可有效減少生醫材料21在進行乾燥步驟所需的時間。當然,上述所述之方法僅為生醫材料21乾燥之一實施例,最終生醫材料21乾燥之方法並不以此為限。In addition, the master mold 30 is constructed in a two-layer structure, and the filling structure 2 has a more detailed manufacturing method, including first injecting the biomedical material 21 solution into the master mold 30, and drying it for several hours to several days. The sponge-like structure of the medical material 21 has a prototype shape. Next, the previously proposed male mold 202 and the female mold 30 are pressed together to produce a uniform dense layer on the upper surface of the biomedical material. After the pressing is completed, before the step of drying the biomedical material, the male mold 202 and the female mold 30 are placed upside down, and the outer mold 302 of the mother mold is taken out, and the inner mold layer 301 is retained, by the plural of the inner mold layer 301. The holes are used to accelerate the material drying process; wherein the step of placing the male mold 202 and the female mold 30 upside down is not necessary, that is, the male mold 202 and the female mold 30 do not necessarily need to be placed upside down. This embodiment can effectively reduce the time required for the biomedical material 21 to perform the drying step. Of course, the method described above is only one example of drying the biomedical material 21, and the method of drying the biomedical material 21 is not limited thereto.
綜上所述,本發明的製作方法可包含步驟(S1)、(S2)、(S3)、(S4)、(S5);另外,也可以下述步驟進行,包含步驟(S1)、(S2)、(S21)、(S22)、(S3)、(S4)、(S5)。In summary, the manufacturing method of the present invention may include steps (S1), (S2), (S3), (S4), (S5); in addition, the following steps may also be performed, including steps (S1), (S2) ), (S21), (S22), (S3), (S4), (S5).
此外,在上述兩種製作方法中,針對步驟(S3),可以用控制公模202溫度而有2種不同的製程選擇。也就是說公模202的溫度控制可為室溫或是70℃~150℃之間,其中當溫度控制在70℃~150℃之間時,生醫材料21可產生熱交聯。並且,也可搭配使用母模201或是以雙層結構方式所構成的母模30來進行製作填充結構2。Further, in the above two manufacturing methods, for the step (S3), there are two different process selections for controlling the temperature of the male mold 202. That is to say, the temperature control of the male mold 202 can be room temperature or between 70 ° C and 150 ° C, wherein the biomedical material 21 can thermally crosslink when the temperature is controlled between 70 ° C and 150 ° C. Further, the filling structure 2 may be produced by using the master mold 201 or the master mold 30 which is formed by a two-layer structure.
綜上所述,本發明之其較具體之製造流程主要可分為:In summary, the more specific manufacturing process of the present invention can be mainly divided into:
(一)單純擠壓,其步驟為(S1)、(S2)、(S3)、(S4)、(S5),其中(S3)公模202溫度為室溫。(1) Simple extrusion, the steps of which are (S1), (S2), (S3), (S4), (S5), wherein (S3) the temperature of the male mold 202 is room temperature.
(二)化學交聯方式與擠壓合併使用,其步驟為(S1)、(S2)、(S21)、(S22)、(S3)、(S4)、(S5),其中(S3)公模202溫度為室溫。(2) The chemical crosslinking method is combined with extrusion, and the steps are (S1), (S2), (S21), (S22), (S3), (S4), (S5), wherein (S3) male mold The temperature of 202 is room temperature.
(三)熱交聯方式與擠壓合併使用,其步驟為(S1)、(S2)、(S3)、(S4)、(S5),其中(S3)公模202溫度控制在70℃~150℃。(3) The thermal crosslinking method is combined with extrusion, and the steps are (S1), (S2), (S3), (S4), (S5), wherein the temperature of the (S3) male mold 202 is controlled at 70 ° C to 150 °C.
(四)化學交聯方式與熱交聯方式以及擠壓合併使用,其步驟為(S1)、(S2)、(S21)、(S22)、(S3)、(S4)、(S5),其中(S3)公模202溫度控制在70℃~150℃。(4) The chemical crosslinking method is combined with the thermal crosslinking method and the extrusion, and the steps are (S1), (S2), (S21), (S22), (S3), (S4), (S5), wherein (S3) The temperature of the male mold 202 is controlled at 70 ° C to 150 ° C.
當然,上述四種製作方法都可選擇使用母模201或是以雙層結構方式所構成的母模30來進行製作填充結構2。Of course, the above four manufacturing methods can be selected to use the master mold 201 or the master mold 30 formed by the two-layer structure to fabricate the filling structure 2.
藉由本發明所製造的填充結構,提供具有不同之緻密度的填充結構製造方法。所述之填充結構可取代現有用於組織修復,解決缺牙問題或是骨科補綴物的問題。也就是說填充結構的用途與製備並不以齒科為限,也可應用於其他科別,比如骨科。以骨科為例,骨頭又可分為外部皮質骨與內部海綿骨,皆可依據需要以所製得的填充結構填入輔助治療。With the filling structure manufactured by the present invention, a filling structure manufacturing method having different densities is provided. The filling structure can replace the existing problems for tissue repair, solving the problem of missing teeth or orthopedic patches. That is to say, the use and preparation of the filling structure is not limited to the dental department, but can also be applied to other departments, such as orthopedics. In the case of orthopedics, the bone can be further divided into an external cortical bone and an internal sponge bone, which can be filled with auxiliary treatment according to the required filling structure.
本發明所提供的填充結構製作方法優點包括可以用較簡單的方式製造出具有不同孔洞大小的填充結構、可提供具有不同之緻密度的填充結構;解決不同材料性質介面黏接的問題:解決使用化學交聯劑(chemical cross-linker)而衍生的問題以及材料來源單一,製程較為簡便,因此在製作填充結構上較快速且較方便。The advantages of the filling structure manufacturing method provided by the invention include that the filling structure with different hole sizes can be manufactured in a relatively simple manner, and the filling structure with different density can be provided; the problem of interface bonding of different material properties can be solved: solving the use The problem of chemical cross-linker and the single source of material, the process is relatively simple, so it is faster and more convenient to make the filling structure.
本發明雖以較佳實例闡明如上,然其並非用以限定本發明的精神與發明實體僅止於上述實施例爾。是以,在不脫離本發明的精神與範圍內所作的修改,均應包括在下述申請專利範圍內。The present invention has been described above by way of a preferred embodiment, and is not intended to limit the spirit of the invention. Modifications made without departing from the spirit and scope of the invention are intended to be included within the scope of the appended claims.
1...人造物1. . . Artificial object
10...膠質海綿體10. . . Glial sponge
11...薄膜11. . . film
20...模具20. . . Mold
201...母模201. . . Master model
202...公模202. . . Public model
21...生醫材料twenty one. . . Biomedical materials
211...上側部份211. . . Upper part
212...下側部份212. . . Lower part
30...母模30. . . Master model
301...母模內層301. . . Inner layer
302...母模外層302. . . Master outer layer
第一圖為習知的填充結構示意圖;The first figure is a schematic diagram of a conventional filling structure;
第二圖為本發明填充結構的製造方法流程圖;The second figure is a flow chart of a manufacturing method of the filling structure of the present invention;
第三圖為本發明一實施例的示意圖。The third figure is a schematic view of an embodiment of the invention.
20...模具20. . . Mold
201...母模201. . . Master model
202...公模202. . . Public model
21...生醫材料twenty one. . . Biomedical materials
211...上側部份211. . . Upper part
212...下側部份212. . . Lower part
Claims (11)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW099111336A TWI475984B (en) | 2010-04-09 | 2010-04-09 | Method for making an infill structure |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW099111336A TWI475984B (en) | 2010-04-09 | 2010-04-09 | Method for making an infill structure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201134461A TW201134461A (en) | 2011-10-16 |
| TWI475984B true TWI475984B (en) | 2015-03-11 |
Family
ID=46751522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW099111336A TWI475984B (en) | 2010-04-09 | 2010-04-09 | Method for making an infill structure |
Country Status (1)
| Country | Link |
|---|---|
| TW (1) | TWI475984B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001164124A (en) * | 1999-10-01 | 2001-06-19 | Kyocera Corp | Resin composite, radio wave absorber using the same, and method of manufacturing the same |
| US20040096475A1 (en) * | 2002-07-09 | 2004-05-20 | Pentax Corporation | Calcium phosphate-synthetic resin composite body containing calcium phosphate block and method for production thereof |
| TWI275402B (en) * | 2005-05-25 | 2007-03-11 | Wen-Neng Weng | Biodegradable porous three-dimensional-support and manufacturing method thereof |
| TW200718435A (en) * | 2005-11-07 | 2007-05-16 | Univ Nat Tsing Hua | Composite scaffold for remedying articular cartilage tissue and preparation thereof |
| TWM369148U (en) * | 2009-04-17 | 2009-11-21 | Body Organ Biomedical Corp | Infill structure for avoiding alveolar bone from atrophying |
-
2010
- 2010-04-09 TW TW099111336A patent/TWI475984B/en not_active IP Right Cessation
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001164124A (en) * | 1999-10-01 | 2001-06-19 | Kyocera Corp | Resin composite, radio wave absorber using the same, and method of manufacturing the same |
| US20040096475A1 (en) * | 2002-07-09 | 2004-05-20 | Pentax Corporation | Calcium phosphate-synthetic resin composite body containing calcium phosphate block and method for production thereof |
| TWI275402B (en) * | 2005-05-25 | 2007-03-11 | Wen-Neng Weng | Biodegradable porous three-dimensional-support and manufacturing method thereof |
| TW200718435A (en) * | 2005-11-07 | 2007-05-16 | Univ Nat Tsing Hua | Composite scaffold for remedying articular cartilage tissue and preparation thereof |
| TWM369148U (en) * | 2009-04-17 | 2009-11-21 | Body Organ Biomedical Corp | Infill structure for avoiding alveolar bone from atrophying |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201134461A (en) | 2011-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105662621B (en) | A kind of porous dental implant and its manufacturing method of drug-carrying slow-released system | |
| CN105530888B (en) | porous dental implant | |
| EP2529702B1 (en) | Reinforced implant made of biocompatible ceramic and method for manufacturing same | |
| JP5564581B2 (en) | Device for covering and / or reconstructing a bone defect site and method for manufacturing the same | |
| US20200375716A1 (en) | Device for guided bone and tissue regeneration | |
| CN205698065U (en) | The porous tooth implant of drug-carrying slow-released system | |
| EP3203934B1 (en) | Synthetic block intended for filling in a bone defect and method for manufacturing same | |
| JP2022088628A (en) | Bone transplant substitute | |
| AU2010319934A1 (en) | Implants and methods for performing gums and bone augmentation and preservation | |
| JP3389316B2 (en) | Absorbable biomaterial and method for producing the same | |
| CN113473943A (en) | Dental device for preserving alveolar ridge and promoting jaw regeneration at extraction site | |
| TWI475984B (en) | Method for making an infill structure | |
| CN103313737A (en) | Devices and methods for tissue engineering | |
| CN112603603A (en) | Personalized prosthesis with antibacterial and bone promoting effects and its preparation method | |
| US8475821B2 (en) | Bone prosthetic material and method of manufacturing the same | |
| US20120065741A1 (en) | Guided tissue regeneration membrane | |
| CN102233636A (en) | Method for manufacturing filling structure | |
| US9833544B2 (en) | Biphasic collagen membrane or capsule for guided tissue regeneration | |
| WO2009045176A1 (en) | Method of making a scaffold for tissue and bone applications | |
| KR101898413B1 (en) | Abutment for Implant using peek&pektton and Manufacturing Method Thereof | |
| CN100446818C (en) | A tissue engineering carrier material using polycaprolactone as raw material and its preparation method | |
| CN111671533B (en) | Assembled root type dental implant with osteogenesis promoting and anti-inflammatory effects and manufacturing method thereof | |
| CN110090320B (en) | Tooth extraction pit repairing support with antibacterial activity and preparation method | |
| CA2773165A1 (en) | High strength, high stiffness, reconstituted collagen membranes for biomedical implantation | |
| JPWO2018115128A5 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |